DexCom stock snapshot and recent performance DexCom (DXCM) has been drawing attention after recent price moves, with the ...

It has had strong momentum since November, but there is still plenty of upside left.

Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...

What Happened? Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper Sandler and Bernstein lowered their price targets on the stock, citing ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BillionToOne, Inc. Class A ( BLLN – Research Report) and Dexcom ( DXCM – Research Report ).

DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2025 revenue of roughly US$4.66 billion, both rising at double-digit ...

DexCom's Q2 earnings report was disastrous, revealing internal sales channel issues and competitive pressures, leading to a Hold rating and lowered price targets. The company's reliance on channel ...